RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.
An expert investor watcher just said BioCryst is not as exciting as before and lowered how high the stock price might go. When experts lose hope in a company, it often means they found reasons to worry about its future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.